（一）主要产品的价格变动情况 证券代码：600328 证券简称：中盐化工 公告编号：（临）2025-034 中盐内蒙古化工股份有限公司 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 中盐内蒙古化工股份有限公司（以下简称"公司"）根据上海证 券交易所《上市公司行业信息披露指引第七号-医药》《上市公司行 业信息披露指引第十八号-化工》及《关于做好上市公司 2025 年第一 季度报告披露工作的通知》要求，现将公司 2025 年第一季度主要经 营数据披露如下： | 主要行业 | 主要产品 | 2025 年第 | 2025 年第 | 营业收入（万 元） | | --- | --- | --- | --- | --- | | | | 一季度产量 | 一季度销量 | | | 精细化工行业 | 金属钠、氯酸钠 （万吨） | 3.40 | 3.29 | 21,343.68 | | 基础化工行业 | 纯碱（万吨） | 104.39 | 95.02 | 121,025.87 | | | 聚氯乙烯树脂 ...

4月24日赛科希德发布2024年度分配预案，拟10派3.3元（含税），预计派现金额合计为3431.01万元。派 现额占净利润比例为30.36%，这是公司上市以来，累计第5次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派3.3元（含税） | 0.34 | 1.32 | | 2023.12.31 | 10派2.6元（含税） | 0.28 | 0.62 | | 2022.12.31 | 10转增3派2.6元（含税） | 0.21 | 0.72 | | 2021.12.31 | 10派2.5元（含税） | 0.20 | 0.48 | | 2020.12.31 | 10派4元（含税） | 0.33 | 0.39 | 证券时报•数据宝统计显示，公司今日公布了2024年报，共实现营业收入3.06亿元，同比增长11.03%， 实现净利润1.13亿元，同比下降3.35%，基本每股收益为1.07元，加权平均净资产收益率为6.91%。 资金面上看，该股今日主力资金净流入85.64万 ...

Core Viewpoint - Huabang Health's 2024 annual report reveals significant financial changes, including a drastic decline in net profit and an increase in the capitalization rate of R&D investment, which warrants close attention from investors [1][19]. Revenue Performance - In 2024, Huabang Health achieved operating revenue of 11,664,669,783.79 yuan, a slight increase of 0.60% from 11,594,590,416.29 yuan in the previous year [2]. - Revenue breakdown by sector shows: - Pharmaceutical sector: 3,058,295,454.21 yuan, 26.22% of total revenue, up 3.15% year-on-year - Agrochemical new materials: 6,592,351,522.38 yuan, 56.52% of total revenue, down 0.87% - Tourism services: 1,103,451,946.30 yuan, 9.46% of total revenue, up 1.70% - Medical sector: 367,421,077.90 yuan, 3.15% of total revenue, up 38.32% [2]. Profitability Issues - The net profit attributable to shareholders was -298,989,917.10 yuan, a significant drop of 198.96% compared to 302,122,026.53 yuan in the previous year, primarily due to asset impairment and losses from investments in associates [3]. - The adjusted net profit, excluding non-recurring items, was -337,852,237.08 yuan, down 238.99% from 243,070,835.37 yuan in the previous year, indicating challenges in core business profitability [4]. Earnings Per Share - Basic earnings per share fell to -0.1514 yuan, a decline of 199.21% from 0.1526 yuan in the previous year, reflecting a severe impact on shareholder returns [5]. - The adjusted earnings per share also showed a significant decline, further indicating a drop in the quality of the company's core business earnings [6]. Expense Management - Total sales expenses decreased by 21.59% to 1,021,953,508.93 yuan, while management expenses slightly decreased by 1.97% to 1,277,742,199.40 yuan [7]. - Financial expenses increased by 17.01% to 270,037,241.97 yuan, indicating a rise in the company's cost of capital [11]. - R&D expenses decreased by 10.45% to 375,319,013.67 yuan, but the capitalization of R&D investments increased by 74%, suggesting a shift in investment strategy [12]. Cash Flow Analysis - The net cash flow from operating activities was 1,625,292,850.24 yuan, a 2.25% increase year-on-year, indicating improved cash generation capabilities [13]. - The net cash flow from investing activities was -1,145,182,910.39 yuan, reflecting a 34.55% increase in cash outflows, suggesting adjustments in investment strategies [15]. - The net cash flow from financing activities decreased significantly, indicating changes in the company's financing strategy and cash recovery needs [16]. Executive Compensation - The chairman and CEO received substantial pre-tax compensation of 1.946 million yuan and 1.846 million yuan, respectively, raising questions about the appropriateness of such compensation amid declining net profits [18].

近日，石药创新制药股份有限公司（股票简称： 新诺威 ）发布了2024年年报。2024年实现营业收入 19.81亿元，同比减少21.98%；实现归母净利润5372.63万元，同比减少87.63%；实现扣非净利润4234.19 万元，同比减少94.31%。 在 医药行业 风云变幻的浪潮中，新诺威这家曾经的市场宠儿正深陷多重困境。2024年年报数据如同一 记重锤，砸向市场，营收与利润的大幅下滑令人咋舌；功能性原料价格波动、 创新药 研发投入高企等 多因素交织，让业绩困境雪上加霜；石药集团一系列资本运作虽在短期内推动股价飙升，却也随着业绩 下滑而面临考验；与此同时，关键岗位的人事变动更是为公司的未来发展增添了诸多变数。新诺威究竟 能否冲破重重迷雾，实现逆袭？ 业绩大幅下滑：多因素交织的困境 单看2024年第四季度，新诺威情况更为严峻。单季度主营收入5.02亿元，同比下降16.57%；单季度归母 净利润-8560.31万元，同比下降262.5%；单季度扣非净利润-9440.05万元，同比下降156.26%。曾经，新 诺威是业绩宠儿，在市场上风光无限，如今却陷入如此困境，令人不禁唏嘘感慨。 新诺威业绩大幅下滑并非偶然，背 ...

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 导读： 当地时间 2025年4月9日，美国对部分中国输美商品累计税率高达104%的 "核弹级"政策正式落地 。 本期 《 视角 》 栏目我们 来聊聊这波猝不及防的"战事"。 据白宫官网公告，美国对中国征收1 0 4%关税将在当地时间周三（4月1 0日）凌晨1 2 : 0 1起生效，并上调了价值8 0 0美元 或以下商品所需缴纳的税额。 迅速恶化的"战况" 这场被专家称为" 2 1世纪最大规模贸易战"的博弈始于2 0 2 5年4月3日， 美国总统特朗普在白宫签署了关于"对等关税"的 行政令， 宣布对所有贸易伙伴设立1 0%的"最低基准关税"，并对部分经济体征收更高税率。亚洲国家成为"重灾区"， 其中 对中国的关税加征幅度高达3 4% 。 此后，事情的发展速度令人始料未及： · 北 京 时 间 4 月 4 日 ， 中 国 国 务 院 关 税 税 则 委 员 会 、 商 务 部 、 海 关 总 署 相 继 出 台 一 系 列 对 美 反 制 措 施 ， 强 硬 " 奉 陪 到 底"。措施内容 ...

小盘股前几天下跌多，今天反弹上涨也略多。 文 | 银行螺丝钉 （转载请注明出处） 昨天微涨的银行等价值风格，今天微跌。 今天大盘整体微涨，截止到收盘，还在5星。 大中小盘股都上涨。 成长风格上涨较多。 医药行业今天上涨较多。医药的几个子行业，医疗、生物科技、创新药等也整体上涨。 这轮熊市底部上涨，科技股率先反弹。 例如恒生科技，在2022年10月触底，之后上涨超1倍。 医药行业2024年5.9星触底，之后反弹，比科技股晚了一年多。 不过今年也有继续上涨的迹象了。 低估品种总会有上涨的阶段。 港股也整体上涨，港股红利股、医药股领涨。 1. [大吉大利，今天吃基] 第358期的螺丝钉定投实盘来啦。 时间：2025年4月1日 方案：定投买入 品种： 指数增强投顾组合：11127元 主动优选投顾组合： 12086元 定投 金额采用的是 「定期不定额」的策略，估值越低投入越多。 实际使用参考金额的时候，可以根据自己的资金，按照一定比例来定投。 例如资金较少的情况下，可以按照10%的金额来投资。 还不了解组合发车计划的朋友，可以点击阅读介绍： 螺丝钉发车计划 PS：组合底层投资基金、各自比例等都是透明的，可以在公众号底部 ...

Core Viewpoint - The pharmaceutical industry is experiencing a rebound driven by technological advancements, particularly in innovative drugs and AI healthcare, marking the best start to the year in nearly four years [1][2]. Group 1: Industry Recovery and Investment Opportunities - The pharmaceutical sector is believed to be in a structural bottoming phase, with many companies emerging from a prolonged downturn, indicating a potential recovery [1][2]. - The AI healthcare and innovative drug sectors are identified as the two core investment tracks for the future, supported by their dual attributes of innovation and technology [6][7]. - The recent strong performance of the pharmaceutical sector, with Hong Kong and A-share innovative drug indices rising over 36% and 15% respectively since January 13, highlights the sector's recovery potential [1]. Group 2: Driving Factors for the Pharmaceutical Sector - Four key factors are driving the anticipated turning point in the pharmaceutical industry: technological advancements, policy effects, internationalization of innovative drugs, and increasing institutional interest [3][4][5]. - Technological advancements, particularly in AI applications for drug development and healthcare, are significantly enhancing market sentiment and investment opportunities [3][4]. - Policy reforms aimed at improving the efficiency of medical insurance funds and promoting high-quality development in the pharmaceutical sector are beginning to yield positive results [4][5]. Group 3: Market Dynamics and Valuation - The internationalization of innovative drugs is accelerating, with over $12.6 billion in License-out transactions reported this year, indicating strong growth potential [5]. - The valuation of innovative drugs is supported by their increasing international presence and ongoing research and development efforts, which are expected to yield new market opportunities [5][6]. - The focus on innovative drugs and AI healthcare is expected to continue, with the potential for significant revenue growth as these sectors mature [6][7]. Group 4: Investment Strategy and Research Approach - The company emphasizes a systematic investment approach, focusing on deep research, long-term perspectives, and broad coverage of the pharmaceutical sector to identify value [9][10]. - The investment team consists of experienced professionals dedicated to thorough analysis and understanding of industry trends, company governance, and business models [9][10]. - The current market conditions present a favorable opportunity for investment in the pharmaceutical sector, particularly in innovative drugs and AI healthcare, despite the inherent challenges [8][11].

Core Points - The CSI All Share Healthcare Index increased by 0.05%, closing at 8642.42 points with a trading volume of 48.652 billion [1] - Over the past month, the index has risen by 0.21%, while it has decreased by 0.61% over the last three months and increased by 1.70% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI All Share Index, categorized into various levels of industries [1] Index Composition - The top ten weighted stocks in the CSI All Share Healthcare Index include: Heng Rui Medicine (6.67%), WuXi AppTec (5.32%), Mindray Medical (4.71%), Aier Eye Hospital (2.04%), Pian Zai Huang (2.0%), United Imaging Healthcare (1.66%), Yunnan Baiyao (1.6%), Kelun Pharmaceutical (1.27%), New Horizon (1.09%), and Shanghai Raist (1.03%) [1] - The market share of the index's holdings is distributed as follows: Shanghai Stock Exchange 50.92%, Shenzhen Stock Exchange 49.04%, and Beijing Stock Exchange 0.04% [2] - The index is composed entirely of the healthcare sector, with a 100% allocation to healthcare [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to changes in the CSI All Share Index [2] - Special events affecting sample companies may lead to corresponding adjustments in the index, including delisting or corporate actions such as mergers and acquisitions [2]

Core Viewpoint - The article discusses the complexities and investment opportunities within the pharmaceutical sector, highlighting the numerous indices available for investors to consider [2][3][17]. Summary by Sections Overview of Pharmaceutical Indices - There are a total of 27 pharmaceutical industry or thematic indices tracked by funds, divided into 12 broad-based indices and 15 thematic indices [2][3]. Traditional Pharmaceutical Indices - Traditional indices include major A-share indices that require profitability for listing, such as: - CSI All Pharmaceutical Index (000991): Covers the entire industry chain, including chemical pharmaceuticals, medical devices, and services [7]. - CSI Pharmaceutical Health Index (000933): Strong industry representation, covering leading companies across the industry chain [7]. - National Pharmaceutical Industry Index (399394): Focuses on 80 prominent stocks in the A-share market [7]. - CSI Pharmaceutical 50 Index (931140): Selects 50 leading pharmaceutical stocks emphasizing R&D investment and market share [8] [9]. Emerging Pharmaceutical Indices - Emerging indices focus on innovative drugs, medical themes, and biotechnology, including: - CSI Innovative Drug Industry Index (931152): Concentrates on companies developing innovative drugs [10]. - National Biopharmaceutical Index (399441): Targets high-growth companies in the biopharmaceutical innovation sector [10]. - CSI Medical Index (399989): Comprises medical devices and services, benefiting from new medical infrastructure and domestic replacements [11]. Current Valuation Levels - As of March 18, 2025, the price-to-earnings (PE) ratios of 12 pharmaceutical indices indicate that most are below their historical averages, suggesting they are not overvalued. Five indices are considered "normal undervalued" while four are "undervalued" [14][15]. Investment Strategies - The article suggests that investors may consider focusing on emerging indices for higher return potential, albeit with greater volatility. Conversely, conservative investors might prefer traditional indices, which also include exposure to emerging sectors [17][18]. - Actively managed pharmaceutical thematic funds have historically outperformed during bull markets and have shown resilience during bear markets, making them a viable option for investors [19].

Investment Rating - The report does not specify a clear investment rating for the company [1][6]. Core Views - The company's performance in 2024 met expectations, with a total revenue of 28.1 billion yuan, a year-on-year decrease of 10.5%, and a net profit attributable to the parent company of 10.5 billion yuan, an increase of 31.3% [6][9]. - The sales of the main product, New Huo Su, experienced a decline, with a total sales revenue of 24.3 billion yuan, down 13.6% year-on-year [6][9]. - The company plans to continue high cash dividends, proposing a cash dividend of 0.728 yuan per share, totaling 630 million yuan, which accounts for 60% of the net profit attributable to shareholders [6][9]. Summary by Sections Financial Performance - Revenue for 2024 was 28.1 billion yuan, with a growth rate of -10.45% [2][9]. - Net profit attributable to the parent company was 10.5 billion yuan, with a growth rate of 31.26% [2][9]. - Earnings per share (EPS) for 2024 was 3.26 yuan [2][9]. - The return on equity (ROE) was 26.75% [2][9]. Future Projections - Revenue projections for 2025-2027 are 29.6 billion yuan, 33.2 billion yuan, and 37.3 billion yuan, respectively, with growth rates of 5.56%, 12.14%, and 12.26% [2][9]. - Net profit projections for 2025-2027 are 9.4 billion yuan, 10.5 billion yuan, and 11.3 billion yuan, respectively [6][9]. Product Sales Forecast - New Huo Su sales are projected to be 25.1 billion yuan in 2025, with a growth rate of 3% [8][9]. - Other product sales are expected to grow significantly, with projections of 452.8 million yuan in 2025, reflecting a growth rate of 21.1% [8][9]. Cost and Profitability - The gross profit margin for 2024 was 94.2%, with a slight decrease expected in the following years [6][9]. - The company aims to control the cost ratio to within 70% for 2025 [6][9].